Compare NRXP & CXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRXP | CXH |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 65.6M |
| IPO Year | N/A | N/A |
| Metric | NRXP | CXH |
|---|---|---|
| Price | $2.10 | $7.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $30.50 | N/A |
| AVG Volume (30 Days) | ★ 455.8K | 25.9K |
| Earning Date | 11-17-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | ★ $242,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | ★ N/A | $33.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $6.41 |
| 52 Week High | $6.01 | $7.74 |
| Indicator | NRXP | CXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 38.53 |
| Support Level | $2.22 | $7.91 |
| Resistance Level | $2.39 | $7.98 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 3.41 | 15.38 |
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.